NLRP3 and lung cancer: In terms of CAMs, Lee et al. [43] reported that lung cancer cells cultured in conditioned medium from BMAL1-deficient CAMs exhibited an enhanced epithelial-mesenchymal transition through NLRP3 inflammasome activation, which could be attenuated by a specific inhibitor of the NLRP3 inflammasome, MCC950.